The effects of heparin and oral anticoagulants on thrombus propagation and prevention of the postphlebitic syndrome: a critical review of the literature.
Based on a comprehensive literature search, this report aims to examine the effects of heparin and oral anticoagulants on thrombus propagation and prevention of the postphlebitic syndrome. The effects on recurrence of thromboembolic disease have not been addressed. It is concluded that published reports of serial venograms and ultrasound examinations of patients treated with conventional anticoagulant therapy for deep venous thrombosis show either no change or thrombus extension in the first few months in approximately 50% of cases. Approximately two thirds of patients will have damage to the venous valves, leading to incompetence or other hemodynamic changes. More than one third of patients so treated may have oedema, leg pain, or other severe symptoms on long-term follow-up. The consistency with which these outcomes have been observed, particularly in many large, recent, prospective trials, adds to the credibility of these figures. The results of prospective controlled trials have failed uniformly to show any significant local benefits of anticoagulant therapy for deep vein thrombosis compared with other treatments or placebo. There does not seem to be any convincing evidence that heparin exerts a favorable influence on pulmonary embolism in situ or on portal vein thrombosis. Use of anticoagulant therapy to limit thrombus propagation therefore cannot be said to be "evidence based." These generally poor outcomes with regard to postphlebitic complications should lead to an active exploration of alternative methods of management. Substantial uncertainties surrounding many fundamental aspects of the treatment of this disease remain, and further placebo-controlled trials are needed.
Egermayer
P
P
Canterbury Respiratory Research Group, Christchurch Hospital, Christchurch, New Zealand.
D000925:Anticoagulants / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D006493:Heparin / Q000627:therapeutic use*; D006495:Heparin, Low-Molecular-Weight / Q000627:therapeutic use; D006801:Humans; D011186:Postphlebitic Syndrome / Q000517:prevention & control*; D013923:Thromboembolism / Q000188:drug therapy*; D015912:Thrombolytic Therapy; D020246:Venous Thrombosis / Q000188:drug therapy
D000925:Anticoagulants; D006495:Heparin, Low-Molecular-Weight; D006493:Heparin